BiotechTube

Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma, Status Asthmaticus

Trial Timeline

Jun 1, 2008 → Mar 1, 2009

NCT ID
NCT00683449

About Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3

Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3 is a phase 2 stage product being developed by MediciNova for Asthma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00683449. Target conditions include Asthma, Status Asthmaticus.

What happened to similar drugs?

20 of 20 similar drugs in Asthma were approved

Approved (20) Terminated (1) Active (0)
✅DuleraMerckApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅levalbuterol HCl + albuterol SulfateSumitomo PharmaApproved
✅arformoterol (RR formoterol) + placebo + levalbuterolSumitomo PharmaApproved
✅Racemic albuterol (R+S albuterol) + Levalbuterol (R albuterol)Sumitomo PharmaApproved
✅BenralizumabAstraZenecaApproved
✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00683449Phase 2Terminated

Competing Products

20 competing products in Asthma

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
40
DuleraMerckApproved
43
BriquilimabJasper TherapeuticsPhase 1
11
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
35
RoflumilastAstraZenecaPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
35
Regadenoson + PlaceboAstellas PharmaApproved
43
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
40
rabeprazoleEisaiPhase 3
40
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
35
Placebo + BrodalumabKyowa KirinPhase 2
27
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
35
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40